We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

7 hedge funds and large institutions have $186K invested in Benitec Biopharma in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

17% more funds holding

Funds holding: 6 → 7 (+1)

3.55% less ownership

Funds ownership: 6.6% → 3.05% (-3.6%)

86% less capital inflows, than outflows

Capital inflows: $93.7K | Capital outflows: $654K

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$51.9K
2
Old Mission Capital
Old Mission Capital
Illinois
+$20.7K
3
Morgan Stanley
Morgan Stanley
New York
+$9.7K
4
UBS Group
UBS Group
Switzerland
+$6.49K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$4.87K

Top Sellers

Rank Fund Capital Flow
1
Highbridge Capital Management
Highbridge Capital Management
New York
-$527K
2
Sphera Funds Management
Sphera Funds Management
Israel
-$127K

BNTC Hedge Fund Activity: Q2 2019 in Review

7 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q2 2019, worth a combined $186K — down 82% from $1.05M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BNTC positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $51.9K. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $527K sold.

  • 7 institutional investors held Benitec Biopharma (BNTC) as of Q2 2019, up from 6 in Q1 2019.
  • Funds reported $186K of Benitec Biopharma stock for Q2 2019, down 82% quarter-over-quarter.
  • 2 funds opened new Benitec Biopharma positions in Q2 2019 and 1 closed out, a net change of +1 holder.
  • The largest Benitec Biopharma buyer in Q2 2019 was Citadel Advisors, an estimated $51.9K added.
  • The largest Benitec Biopharma seller in Q2 2019 was Highbridge Capital Management, an estimated $527K sold.

Based on aggregated 13F filings for Q2 2019.